Invitris Analysis: $125K Raised
What is Invitris?
Invitris develops synthetic proteins using a universal platform technology, focusing on human therapeutics and industrial applications with high yields and purity.
Employees
6
Founded
2022
Product Features & Capabilities
- human therapeutics, industrial applications, synthetic proteins, phages, tailocins, endolysins, neoantigens, vaccines, antibodies, toxic proteins (nucleases, proteases), prokaryotic cell-free expression systems, eukaryotic cell-free expression systems, applications in human health, agriculture, anim
How much Invitris raised
1 - $125K
2023Lead Investor: Y Combinator
Who are the founders of Invitris
PG
Patrick Grossman
CEO & Co-Founder
KV
Kilian Vogele
CTO & Co-Founder
Business Model
Partnerships for product development; revenue from sales of synthetic proteins and services.
Competitors Overview
The main competitors of Invitris in the synthetic protein market include:
- Thermo Fisher Scientific, Inc.: A leading provider of scientific instruments, reagents, and consumables, Thermo Fisher offers a wide range of products for protein synthesis and cell-free expression technologies. Their
Market Focus
Invitris primarily focuses on the biotechnology industry, specifically in the development and manufacturing of synthetic proteins for human therapeutics and industrial applications.
Investors
- 10x Founders
- another.vc
- European Innovation Council Fund
- Mergus Ventures
- Phoenix Investment
See something that needs updating? Suggest edits to this profile.